Scientific and Regulatory Aspects of Macromolecular Drugs and Devices

REFERENCES

• Edrnond, S. K., Grady, L. T., Outschoorn, A. S., Rhodes, C. T., (1986). Monoclonal Antibodies as Drugs and Devices, Drug Develop. Ind. Pharm., 12 (1 and 2), 107–228.
   Google Scholar
• Elander, R. P., (1985). Biotechnology: Present and Future Roles in the Pharmaceutical Industry, Drug Develop. Ind. Pharm., 11:5, 965–999.
   Google Scholar
• “Hormone Drugs,” Proceedings of FDA-USP Workshop, May 1982, United States Pharmacopeia Convention, Inc., Maryland, (1982).
   Google Scholar
• “Impacts of Applied Genetics, Microorganisms, Plants and Animals,” United States Congress, Office of Technology Assessment, Washington, D. C. (1981).
   Google Scholar
• “Insulins, Growth Hormone and Recombinant DNA Technology,” ed., John L. Gueriguian, Raven, New York, (1981).
   Google Scholar
• “Monoclonal Hybridoma Antibodies: Techniques and Applications,” ed., John G. R. Hurrell, CRC, Florida, (1982).
   Google Scholar
• “Recombinant DNA Products: Insulin, Interferon and Growth Hormone,” ed., Arthur P. Bollon, CRC, Florida, (1984).
   Google Scholar
• Watson, J. D., Tooze, J., Kurtz, D. T., “Recombinant DNA, a Short Course,” Scientific American, New York, (1983).
   Google Scholar
• Berman, P. W., Lasky, L. A., (1985). Engineering Glycoproteins for use as Pharmaceuticals, Trends Biotech., 3:2, 51–53.
   Web of Science ®Google Scholar
• Blundell, T., Sternberg, M. J. E., (1985). Computer-aided Design in Protein Engineering, Trends Biotech., 3:9.
   Google Scholar
• Burke, D. C, (1985). The Interferons, Br. Med. Bulletin, 41:4, 333–338.
   Web of Science ®Google Scholar
• Depinho, R. A., Feldman, L. B., Scharff, M. D., (1986). Tailor-Made Monoclonal Antibodies, Ann. Intern. Med., 104, 225–233.
   Web of Science ®Google Scholar
• Harris, W. J., Strategies for Selection of Appropriate Biotechnologies for Industrial Applications, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 9–25.
   Google Scholar
• Hinman, A. R., Bart, K. J., Orenstein, W. A., (1985). New Vaccines, Int. J. Epid., 14: 4, 502–503.
   Web of Science ®Google Scholar
• Hitzeman, R. A., Leung, D. W., Perry, L. J., Kohr, W. J., Levine, H. L., Goeddel, D. V., (1983). Secretion of Human Interferons by Yeast, Science, 219, 620–625.
   Google Scholar
• Inada, Y., Yoshimoto, T., Matsushima, A., Saito, Y., (1986). Engineering Physicochemical and Biological Properties of Proteins by Chemical Modification, Trends Biotech., 4:3, 68–73.
   Web of Science ®Google Scholar
• Johnson, I. S., (1983). Human Insulin from Recombinant DMA Technology, Science, 219, 632–637.
   Google Scholar
• Keus, J. A. R., (1986). An Accidental Human Trial of Recombinant Vaccina Virus: A Step Towards Acceptance of Live Recombinant Vaccines?, Trends Biotech., 4:5.
   Google Scholar
• Khachatourians, G. G., Haffie, T. L., Biotechnology: Applications to Genetics, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 243–249.
   Google Scholar
• Klausner, A., (1986). Researchers Probe Second-Generation t-PA, Bio/Tech., 4, 706–711.
   Google Scholar
• Nowinski, R. C, Tarn, M. R., Goldstein, L. C, Stong, L., Kuo, C, Corey, L., Stamm, W. E., Handsfield, H. H., Knapp, J. S., Holmes, K. K., (1983). Monoclonal Antibodies for Diagnosis of Infectious Diseases in Humans, Science, 219, 637–644.
   Google Scholar
• Sadee, W., (1986). Protein Drugs: A Revolution in Therapy?, Pharm. Res., 3:1, 3–6.
   Google Scholar
• Scott, M. G., (1985). Monoclonal Antibodies-Approaching Adolescence in Diagnostic Immunoassays, Trends Biotech., 3:7, 170–174.
   Web of Science ®Google Scholar
• Ulmer, K. M., (1983). Protein Engineering, Science, 219, 666–670.
   Google Scholar
• Van Brunt, J., (1986). Neuropeptides: The Brain's Special Messengers, Bio/tech., 4.
   Google Scholar
• Van Brunt, J., (1986). Protein Architecture: Designing from the Ground Up, Bio/tech., 4, 277–283.
   Google Scholar
• Vournakis, J. N., Elander, R. P., (1983). Genetic Manipulation of Antibiotic-Producing Microorganisms, Science, 219, 703–708.
   Google Scholar
• Yelverton, E., Norton, S., Obijeski, J. E., Goeddel, D. V. (1983). Rabies Virus Glycoprotein Analogs: Biosynthesis in Escherichia coU, Science, 219, 614–619.
   Google Scholar
• Arathoon, W. R., Birch, J. R., (1986). Large-Scale Cell Culture in Biotechnology, Science, 232, 1390–1395.
   Google Scholar
• Bebbington, C, Hentschel, C, (1985). The Expression of Recombinant DMA Products in Mammalian Cells, Trends Biotech., 3:12.
   Google Scholar
• Birch, J. R., Boraston, R., Wood, L., (1985). Bulk Production of Monoclonal Antibodies in Fermenters, Trends Biotech., 3:7, 162–166.
   Web of Science ®Google Scholar
• Bok, S. H., (1985). Improving the Production of Recombinant DNA Proteins Through Fermentation Development, Pharm. Manufac, Jan., 40–42.
   Google Scholar
• Borrebaeck, C. A. K., (1986). In vitro Immunisation for Production of Murine and Human Monoclonal Antibodies: Present Status, Trends Biotech., 4:6, 147–152.
   Web of Science ®Google Scholar
• Browne, M. J., Dodd, I., Carey, J. E., Chapman, C. G., Robinson, J. H., (1985). Increased Yield of Human Tissue-Type Plasminogen Activator Obtained by Means of Recombinant DNA Technology, Thromb. Hemost., 54:2, 422–424.
   PubMed Web of Science ®Google Scholar
• Burnett, K. G., Martinis, J., Bartholomew, R. M., Production of Bifunctional Antibodies by Hybridoma Technology, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 401–409.
   Google Scholar
• Caulcott, C. A., Rhodes, M., (1986). Temperature-Induced Synthesis of Recombinant Proteins, Trends Biotech., 4:6, 142–146.
   Web of Science ®Google Scholar
• Chisti, Y., Moo-Young, M., (1986). Disruption of Microbial Cells for Intracellular Products, Enzyme Microb. Technol., 8:4, 194–204.
   Google Scholar
• Cooney, C. L., (1983). Bioreactors: Design and Operation, Science, 219, 728–733.
   Google Scholar
• Crawford, M. A., Johnson, R. W., (1985). Contamination Control in a Class 100 Tissue Culture Media Production Facility, Pharm. Manufac, Jan., 33–37.
   Google Scholar
• Duff, R. G., (1985). Microencapsulation Technology: A Novel Method for Monoclonal Antibody Production, Trends Biotech., 3:7.
   Google Scholar
• Feder, J., Tolbert, W. R., (1983). The Large-Scale Cultivation of Mammalian Cells, Scientific American, 248:1, 36–43.
   PubMed Web of Science ®Google Scholar
• Fleischaker, R. J., (1986). Applying Large-Scale Culture Techniques to the in vitro Production of Monoclonal Antibodies, Pharm. Manufac, Jan., 16–21.
   Google Scholar
• Giorgio, R. J., Wu, J. J., (1986). Design of Large Scale Containment Facilities for Recombinant DNA Fermentations, Trends Biotech., 4:3, 60–65.
   Web of Science ®Google Scholar
• Hartmeier, W., (1985). Immobilized Biocatalysts-From Simple to Complex Systems, Trends Biotech., 3:6, 149–152.
   Web of Science ®Google Scholar
• Jarvis, A. P., Grdina, T. A., (1983). Production of Biologicals from Microencapsulated Living Cells, Biotechniques, March-April, 22–27.
   Google Scholar
• Jay, E., Rommens, J., Jay, G., Synthesis of Mammalian Proteins in Bacteria, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 388–399.
   Google Scholar
• Karubie, I., Biosensors in Fermentation and Environmental Control, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 135–155.
   Google Scholar
• Kronenberg, L. H., Interferons: Manufacture and Application in Medicine, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 451–461.
   Google Scholar
• Mizrahi, A., (1986). Biologicals from Animal Cells in culture, Bio/tech., 4, 123–127.
   Google Scholar
• Muth, W. L., Large-Scale Fermentation development of Recombinant Microorganisms, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 156–164.
   Google Scholar
• Posillico, E. G., (1986). Microencapsulation Technology for Large-Scale Antibody Production, Bio/tech., 4, 114–117.
   Google Scholar
• Ratafia, M., (1986). Current Issues in the Scale-Up of Biotechnology Processes, Pharm. Tech., June, 42–52.
   Google Scholar
• Reuveny, S., Zheng, Z. B., Eppstein, L., (1986). Evaluation of a Cell Culture Fermenter, Am. Biotech. Lab., Jan/Feb, 28–39.
   Google Scholar
• Van Brunt, J., (1985). Scale-Up: The Next Hurdle, Bio/tech., 3:5, 419–424.
   Google Scholar
• Van Brunt, J., (1986). Fermentation Economics, Bio/tech., 4:5, 395–401.
   Google Scholar
• Van Brunt, J., (1986). Immobilized Mammalian Cells: The Gentle Way to Productivity, Bio/tech., 4:6, 505–510.
   Google Scholar
• Weetall, H. H., Pitcher, W. H., (1986). Scaling Up an Immobilized Enzyme System, Science, 232, 1396–1403.
   Google Scholar
• Albert, W. H. W., Krueger, D., (1986). Quality Assurance of Therapeutics Based on Monoclonal Antibodies, An European Viewpoint. Boehringer Mannheim GmbH, Biochemical Research Center, D-8132, Tutzing, Germany, F. R.
   Google Scholar
• Alving, B. M., Finlavm, J. S., (1979). Immunoglobulins: Characteristics and Use of Intravenous Preparations, FDA, Bureau of Biologies.
   Google Scholar
• Bethell, D. R., Dawson, M., Lafoe, M. J., (1985). Characterization of Monoclonal Antibodies to Cell Surface Antigens by Particle Concentration Fluorescence Immunoassay (PCFIA), Biotechniques, 3:6, 466–473.
   Google Scholar
• Birch, J. R., Hill, C. R., Kenney, A. C, Affinity Chromatography: Its Role in Industry, in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette, (1985), 594–605.
   Google Scholar
• Collen, D., Rijken, D. C, Van Damme, J., Billiau, A., (1982). Purification of Human Tissue-Type Plasminogen Activator in Centigram Quantities from Human Melanoma Cell Culture Fluid and its Conditioning for Use in-vivo, Thromb., Hemost., 48:3, 294–296.
   PubMed Web of Science ®Google Scholar
• Fung, H-L., Chapter seven in “Modern Pharmaceutics,” eds., Gilbert S. Banker and Christopher T. Rhodes, Marcel Dekker Inc., (1979).
   Google Scholar
• Gooding, R. P., Bristow, A. F., (1985). Detection of Host-Derived Contaminants in Products of Recombinant DNA Technology in E. coli: A Comparison of Silver Staining and Immunoblotting, J. Pharm. Pharmacol., 37, 781–786.
   PubMed Web of Science ®Google Scholar
• Grau, U., (1985). Fingerprint Analysis of Insulin and Proinsulins, Diabetes, 34, 1174–1180.
   PubMed Web of Science ®Google Scholar
• Gubler, U., Chua, A. O., Stern, A. S., Hellmann, C. P., Vitek, M. P., Dechiara, T. M., Benjamin, W. R., Collier, K. J., Dukovich, M., Familletti, P. C, Fiedler-Nagy, C, Jenson, J., Kaffka, K., Kilian, P. L., Stremlo, D., Wittreich, B. H., Woehle, D. Mizel, S. B., Lomedico, P. T., (1986). Recombinant Human Interleukin 1: Purification and Biological Characterization, J. Immunol., 136:7, 2492–2497.
   Web of Science ®Google Scholar
• Hayakawa, T., Kawamura, J., (1983). The Product Quality Assurance Criteria for the Medically Important Polypeptides Produced by Recombinant DNA Technology, Iyakuhin Kenkyu, 14:2, 171–191.
   Google Scholar
• Hou, K. C, Mandaro, R. M., (1986). Bioseparation by Ion Exchange Cartridge Chromatography, BioTechniques, 4:4, 358–367.
   Web of Science ®Google Scholar
• Hunkapiller, M. W., Hood, L. E., (1983). Protein Sequence Analysis: Automated Microsequencing, Science, 219, 650–659.
   Google Scholar
• Hustedt, M., Kroner, K. H., Menge, U., Kula, M-R., (1985) Protein Recovery Using Two-Phase Systems, Trends Biotech., 3:6, 139.
   Web of Science ®Google Scholar
• Kadam, K. L., (1986). Reverse Micelles as a Bioseparation Tool, Enzyme Microb. Technol., 8, 266–273.
   Google Scholar
• Kirkwood, T. B. L., (1977). Predicting the Stability of Biological Standards and Products, Biometrics, 33, 736–742.
   PubMed Web of Science ®Google Scholar
• Kurokawa, M., (1979). J. Biological Standardization, 7, 31–41.
   PubMedGoogle Scholar
• “Monoclonal Antibodies: Standardization of their Characterization and Use.” Developments in Biological Standardization. Vol. 57 (1985), ed., The International Association of Biological Standardization.
   Google Scholar
• Patel, P. R., Enzyme Isolation and Purification in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette (1985), 534–562.
   Google Scholar
• Porterfield, R. I., (1984). Application of kinetic models and Arrhenius methods to product stability evaluation, Pharm. Technol., 45–50.
   Google Scholar
• Proceedings of the 26th Annual Conference of Pharmaceutical Analysis, July 1986, Merrimac, Wisconsin: sponsored by The School of Pharmacy, University of Wisconsin-Madison.
   Google Scholar
• Rhodes, C. T., (1984). An overview of kinetics for the evaluation of pharmaceutical systems, Drug Develop. Ind. Pharm., 8 and 9, 1163–1174.
   Google Scholar
• Rhodes, W. E., (1985). Monoclonal Antibodies for in-vivo Use: In-Process and Final Testing, Pharm. Manufac, April, 12–14.
   Google Scholar
• Rhodes, W. E., (1985). Routine Release Testing for in-vivo Monoclonal Antibodies, Pharm. Manufac, May, 12–14.
   Google Scholar
• Rijken, D. C, Collen, D., (1981). Purification and Characterization of the Plasminogen Activator Secreted by Human Melanoma Cells in Culture, J. Biol. Chem., 256: 13, 7035–7041.
   Web of Science ®Google Scholar
• Roseto, A., Guillemin, M-C, Chehimi, J., Mazeron, M. C., Peries, J., (1984). Elimination of Mycoplasma, Bacteria, and Fungi Contaminants of Hybridoma Cultures by Intraperitoneal Passage in the Mouse, Hybridoma, 3:3, 297–299.
   PubMed Web of Science ®Google Scholar
• Sofer, G. K., (1986). Current Applications of Chromatography in Biotechnology, Bio/tech., 4, 712–715.
   Google Scholar
• “Standardization and Control of Biologicals Produced by Recombinant DNA Technology.” Developments in Biological Standardization Vol. 59 (1985), ed., The International Association of Biological Standardization.
   Google Scholar
• Sulkowski, E., (1985). Purification of Proteins by IMAC, Trends Biotech., 3:1, 1–6.
   Web of Science ®Google Scholar
• Tydeman, M. S., Kirkwood, T. B. L., (1984). Design and analysis of accelerated degradation tests for the stability of biological standards, J. Biological Standardization, 12, 195–206.
   PubMedGoogle Scholar
• Wolfe, A. J., Worthington, H. F. C, (1976). Use of the Arrhenius equation, Drug Develop. Ind. Pharm., 1, 185–194.
   Google Scholar
• Wong, B. L., Charm, S. E., (1983). Product Recovery from Genetically Engineered Organisms: A Review of the Practical Problems, Genet. Eng. News, March/April.
   Google Scholar
• Benson, R. H., (1986). Biotechnology Patent Pit Falls, Bio/tech., 4.
   Google Scholar
• Bliem, R., (1986). ESACT '85 Meeting Report, Products from transformed Cell Lines: The Stance of WHO and FDA, Trends Biotech., 4:1, 1–2.
   Google Scholar
• Gartland, W. J., Government Guidelines in “Biotechnology Applications and Research,” Technomic, eds., Cheremisinoff and Ouellette (1985), 29–40.
   Google Scholar
• Gibbs, J. N., (1986). Regulating Bioengineered Veterinary Drugs Bio/tech., 4, 414–416.
   Google Scholar
• Halperin, J. A., (1985). Helping Drug Regulatory Authorities tc Help You, Clin. Res. Practices and Drug Reg. Affairs, 3:2, 167–184.
   Google Scholar
• Korwek, E. L., (1982). FDA, OSHA, and EPA Regulation of the Recombinant DNA Technology, J. Parenteral Sci. Technol., 36:6, 251–255.
   Google Scholar
• Linhardt, R. J., (1986). Protein Engineering and Site-Directed Mutagenesis, Patents, Applied Biochem. Biotech. 13, 75–79.
   Google Scholar
• Miller, H. I., (1982). Recombinant DNA as a Paradigm of New Technology: Its Impact on Regulation by the Food and Drug Administration, J. Parenteral Sci. Technol., 36:6, 248–250.
   Google Scholar
• Rhodes, W. E., (1985). Monoclonal Antibodies as Drugs: A Manufacturing and Regulatory Overview, Pharm. Manufac, Jan
   Google Scholar
• Petricciani, J. C., (1985). Regulatory Considerations for Products Derived from the New Biotechnology, Pharm. Manufac, March, 31–34.
   Google Scholar
• Federal Register, Vol. 51, No. 123, Thursday, June 26, 1986. Part II, Office of Science and technology Policy, “Coordinated Framework for Regulation of Biotechnology: Announcement of Policy and Notice for Public Comment. “
   Google Scholar
• Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology. (1985). Office of Biologies Research and Review, Center for Drugs and Biologies, Food and Drug Administration (FDA), Bethesda, MD 20205.
   Google Scholar
• Points to Consider in the Manufacture of Monoclonal Antibody Products for Human Use (1983). Office of Biologies, FDA.
   Google Scholar
• Points to Consider in the Manufacture of in-vitro Monoclonal Antibody Products Subject to Licensure. (1983). Office of Biologies, FDA.
   Google Scholar
• Points to Consider in the Production and Testing of Interferon Intended for Investigational Use in Humans (1983). Office of Biologies, FDA.
   Google Scholar
• Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (1984). Office of Biologies, FDA.
   Google Scholar
• Guideline on General Principles of Process Validation (1984). Division of Drug Quality Compliance, Office of Drugs, FDA.
   Google Scholar
• Blumenthal, D., Gluck, M., Louis, K. S., Stoto, M. A., Wise, D., (1986). University-Industry Research Relationships in Biotechnology: Implications for the University, Science, 232, 1361–1366.
   Google Scholar
• Dibner, M. D., (1986). Biotechnology in Europe, Science, 232, 1367–1372.
   Google Scholar
• Dibner, M. D., (1985). The Biotech Connection, Pharm. Exec. Sept., 81–84.
   Google Scholar
• Elander, R. P., (1985). Biotechnology: Present and Future Roles in the Pharmaceutical Industry, Drug Develop. Ind. Pharm., 11:5, 965–999.
   Google Scholar
• Evans, S., Grassam, P., (1986). Considerations for Parenteral Dosage Form Development of Natural Alpha Interferon, J. Parenteral Sci. Technol., 40:3, 83–87.
   Google Scholar
• Harford, S., (1983). Recombinant DNA Technology and The Pharmaceutical Industry, The Pharm. J., London, Sept. 17, 320.
   Google Scholar
• Klausner, A., (1985). Words of Caution as Monoclonals Mature, Bio/tech., 4, 604.
   Google Scholar
• Murray, J. R., (1986). The First $4 Billion is the Hardest, Bio/tech., 4, 293–296.
   Google Scholar
• Norris, C. E., (1986). Tax and the Business of Biotechnology, Trends Biotech., 4:7, 169–172.
   Web of Science ®Google Scholar
• Prescott, L., (1983). Hybritech: Portrait of a Monoclonal Specialist, Bio/tech., April, 156–161.
   Google Scholar
• Van Brunt, J., (1986). Contract Production: Buying Technical Expertise, Bio/tech., 4, 701–705.
   Google Scholar